Navigation Links
Biocon Unveils Renal Therapies for Kidney Disorders

India's premier biotechnology firm Biocon Ltd Thursday announced the launch of renal therapy products for treating kidney disorders and reducing// the risk of such disease.

As the leading producer of immuno-suppressants in the subcontinent, the company has set up a nephrology division to market the new products -- Renodapt (Mycophenolate Mofeti), Tacrograf (Tacrolimus), Cyclophil Me (Cyclosporine micro emulsion), Rapacan (Sirolimus) and Erypro (rHuEpo).

"Our renal therapy will enable patients with transplanted kidneys to become immune to any side effects and make them feel compatible with the new organ. Similarly, Erthropoetin (Epo) will increase the hameoglobin level to develop resistance," Bicon chairperson Kiran Mazumdar-Shaw said at a preview of the product.

Prior to the launch, the company has undertaken extensive trials as per the statutory guidelines to demonstrate the safety and efficacy profile of its products. About 300 kidney patients who were administered the drugs responded well to the treatment.

"Our objective is to protect life affected by kidney failures with biotherapeutics and reduce the risk of the disease in future through research and innovative therapies," Shaw said.

Studies have revealed that kidney disease has grown to be a silent epidemic in the 21st century. Every year millions of people across the world are diagnosed with end stage renal disease (ESRD) necessitating kidney treatments.

"The total market size for nephrology products is about Rs.3 billion and is growing by about 20 percent annually. Of these, the market for immuno-suppressants is about Rs.1.25 billion. We are targeting a market share of 20-25 percent in the next three-five years despite aggressive competition from Indian and multinational players in the country," Biocon marketing president Rakesh Bamzai said.

According to "Kidney International", the official journal of the international societ y of nephrology, the incidence of ESRD is likely to be higher in India than in the developed countries, with gloerulonephritis being the most common cause, accounting for one-third of patients, while diabetic nephropathy accounts for about one-fourth of patients.

"In the absence of national registries, no reliable data is available on the incidence and prevalence of ESRD in India. Treatment of ESRD is a low priority for the cash-strapped public hospitals and in the absence of health insurance plans, less than 10 percent of all patients receive any kind of renal replacement therapy," Shaw added.

Source-IANS
'"/>




Related medicine news :

1. Biocon to colloborate for development of Oral peptide drugs for heart diseases.
2. Biocon To Raise Its Investment In Scotland
3. Biocon To Shift Focus On Innovation To Accelerate Growth
4. Kalam Dedicates New Cancer Drug Developed By Biocon
5. Bayer to Market Biocon Insulin in China
6. Biocon Launches Anti-Cancer Drug
7. Biocon to Launch Anti-arthritis Drug
8. Biocon Net Profit Up by 15 Percent for Fiscal Year
9. Study Unveils New Insight To The Madness Of King George III
10. Bush Unveils Latest Blueprint for Handling Bird Flu Pandemic
11. Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorbā„¢process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Allianceā„¢ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
Breaking Medicine Technology: